P.D.Cani, “Human Gut Microbiome: Hopes, Threats and Promises,”Gut67, no. 9 (2018): 1716–1725.
2.
B.Kim and J.Chun, “Current Status and Future Promise of the Human Microbiome,”Pediatric Gastroenterology, Hepatology and Nutrition16, no. 2 (2013): 71–79.
3.
Y.Song, P.Wang, and A.Parian, et al., “Where Will Fecal Microbiota Transplantation Fit in the Treatment Algorithms for Crohn's Disease and Ulcerative Colitis: A Synthesis of Completed, Ongoing and Future Trials,”Gastroenterology154, no. 1, Supp. (2018): S90.
4.
W.J.Lee, L.D.N.Lattimer, and S.Stephen, et al., “Fecal Microbiota Transplantation: A Review of Emerging Indications beyond Relapsing Clostridium difficile Toxin Colitis,”Gastroenterology and Hepatology11, no. 1 (2015): 24–32.
5.
X.Zhanget al., “Efficacy and Safety of Fecal Microbiota Transplantation in Patients with Rheumatoid Arthritis Refractory to Methotrexate,”ClinicalTrials.gov, available at <https://clinicaltrials.gov/ct2/show/NCT03944096> (last visited September 25, 2019).
6.
S.Zhang, S.Palazuelos-Munoz, and E.M.Balsells, et al., “Cost of Hospital Management of Clostridium difficile Infection in United States — a Meta-Analysis and Modelling Study,”BMC Infectious Diseases 16 (2016): 447. doi: 10.1186/s12879-016-1786-6.
7.
L.C.McDonald, D.N.Gerding, and S.Johnson, et al., “Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA),”Clinical Infectious Diseases66, no.7 (2018): e1–e48.
I.A.Myles, K.W.Williams, and J.D.Reckhow, et al., “Transplantation of Human Skin Microbiota in Models of Atopic Dermatitis,”JCI Insight1, no. 10 (2016): e86955, available at <https://dx.doi.org/10.1172/jci.insight.86955> (last visited September 25, 2019).
10.
E.Sohn, “Skin Microbiota's Community Effort,”Nature563 (2018): S91.
11.
M.M.Nascimento, “Oral Microbiota Transplant: A Potential New Therapy for Oral Diseases,”Journal of the California Dental Association45, no. 10 (2017): 565–568.
12.
AndersMårtenssonet al., “Sinonasal Microbiome Transplant as a Therapy for Chronic Rhinosinusitis without Nasal Polyps (CRSsNP),”ClinicalTrials.gov, available at <https://clinical-trials.gov/ct2/show/NCT03122795> (last visited September 25, 2019).
13.
U.S. Food and Drug Administration, “Guidance for Industry: Enforcement Policy Regarding Investigational New Drug Requirements for Use of Fecal Microbiota for Transplantation to Treat Clostridium difficile Infection Not Responsive to Standard Therapies,”78Federal Register42,965 (July18, 2013).
14.
U.S. Food and Drug Administration, “Enforcement Policy Regarding Investigational New Drug Requirements for Use of Fecal Microbiota for Transplantation to Treat Clostridium difficile Infection Not Responsive to Standard Therapies, March 2016,”available at <https://www.fda.gov/media/96562/download> (last visited September 25, 2019).
15.
Id.
16.
National Institutes for Allergies and Infectious Diseases, Grant No. R21AI119633.
17.
The co-investigators included Diane E.Hoffmann(PI) School of Law; FrancicPalumbo, School of Pharmacy; JacquesRavel1, School of Medicine; and Mary-ClairRoghman and Ericvon Rosenvinge, School of Medicine and Veteran Affairs Maryland Health Care System, Baltimore.
18.
D.E.Hoffmann, F.B.Palumbo, and J.Ravel, et al., “Improving Regulation of Microbiota Transplants,”Science358, no. 6369 (2017): 1390–1391.
19.
A.Khoruts, D.E.Hoffmann, and F.B.Palumbo, “The Impact of Regulatory Policies on the Future of Fecal Microbiota Transplantation,”Journal of Law, Medicine & Ethics47, no. 4 (2019): 482-504.
20.
P.Ossorio and Y.Zhou, “FMT and Microbial Medical Products: Generating High-Quality Evidence through Good Governance,”Journal of Law, Medicine & Ethics47, no. 4 (2019): 505-523.
21.
A.Scheeler, “Where Stool is a Drug: International Approaches to Regulating the use of Fecal Microbiota for Transplantation,”Journal of Law, Medicine & Ethics47, no. 4 (2019): 524-540.
22.
T.S.Murray and J.Herbst, “The Ethics of Fecal Microbiota Transplant as a Tool for Antimicrobial Stewardship Programs,”Journal of Law, Medicine & Ethics47, no. 4 (2019): 541-554.
23.
K.DeLonget al., “Vaginal, “Microbiota Transplantation: The Next Frontier,”Journal of Law, Medicine & Ethics47, no. 4 (2019): 555-567.
24.
N.Muelleret al., “Bacterial Baptism: Scientific, Medical and Regulatory Issues Raised by Vaginal Seeding of C-Section-Born Babies,”Journal of Law, Medicine & Ethics47, no. 4 (2019): 568-578.
